Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
33%(3 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_3
3
27%
Ph not_applicable
2
18%
Ph phase_4
2
18%
Ph phase_2
3
27%

Phase Distribution

0

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution10 total trials
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(1)
Other(1)

Detailed Status

Completed9
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (30.0%)
Phase 33 (30.0%)
Phase 42 (20.0%)
N/A2 (20.0%)

Trials by Status

terminated19%
unknown19%
completed982%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11